Close
New

Medscape is available in 5 Language Editions – Choose your Edition here.

 

Vogt-Koyanagi-Harada Disease

  • Author: R Christopher Walton, MD; Chief Editor: Hampton Roy, Sr, MD  more...
 
Updated: Apr 15, 2016
 

Background

Vogt-Koyanagi-Harada (VKH) disease is a multisystemic disorder characterized by granulomatous panuveitis with exudative retinal detachments that is often associated with neurologic and cutaneous manifestations. VKH disease occurs more commonly in patients with a genetic predisposition to the disease, including those from Asian, Middle Eastern, Hispanic, and Native American populations. Several human leukocyte antigen (HLA) associations have been found in patients with VKH disease, including HLA-DR4, HLA-DR53, and HLA-DQ4. (See Etiology and Epidemiology.)[1, 2, 3, 4, 5]

Independently, Vogt, Koyanagi, and Harada described several patients during a 20-year period with bilateral uveitis, exudative retinal detachments, neurologic abnormalities, and disorders of the integument. Despite differences in their patients, the manifestations appeared to represent a spectrum of disease, and several authors suggested that the disorder should be termed Vogt-Koyanagi-Harada syndrome (see the image below). (See Presentation and Workup.)[6, 7, 8, 9, 10]

Bilateral, multifocal serous detachments in a pati Bilateral, multifocal serous detachments in a patient with Vogt-Koyanagi-Harada disease. Disc hyperemia is evident in the right eye.

With such a wide spectrum of manifestations, typical cases of VKH disease are uncommon. To help clarify the diagnostic features of VKH disease, the International Committee on Nomenclature established revised criteria for the diagnosis of VKH disease. The revised criteria defined the following 3 categories of disease[11, 12] :

  • Complete VKH disease
  • Incomplete VKH disease
  • Probable VKH disease

Common to all forms of VKH disease are the following requirements, with additional criteria provided below for each form of the disease (see Presentation and Workup):

  • Patients have no prior history of ocular trauma or surgery
  • Patients have no evidence of another ocular disease based on clinical or laboratory evidence
  • Patients have bilateral ocular involvement.

Complete VKH disease

Early manifestations of complete VKH disease include diffuse choroiditis, which may include serous retinal detachment or focal areas of subretinal fluid. Patients without these findings must have diffuse choroidal thickening—as seen using ultrasonography—with fluorescein angiographic abnormalities, including focal areas of delayed choroidal perfusion, multifocal pinpoint leakage, areas of placoid hyperfluorescence, pooling of subretinal fluid, and optic nerve staining.

Late manifestations of complete VKH disease include evidence of previous early manifestations of the disease, as outlined above, with ocular depigmentation and nummular chorioretinal scars, retinal pigment epithelium (RPE) clumping and migration, or anterior uveitis.

Patients with complete VKH disease must also have evidence of neurologic and auditory manifestations, as well as integumentary signs. However, the neurologic and auditory manifestations may resolve before an ophthalmic examination.

The neurologic and auditory signs include the following:

  • Meningismus - Malaise, fever, headache, nausea, abdominal pain, stiffness of the neck and back, or a combination of these factors; headache alone is not sufficient to meet the definition of meningismus
  • Tinnitus
  • Cerebrospinal fluid pleocytosis

Integumentary signs include the following:

  • Alopecia
  • Poliosis
  • Vitiligo

However, the integumentary signs should not occur prior to the onset of ocular signs and central nervous system signs.

Incomplete VKH disease

Patients with incomplete VKH disease have either neurologic and auditory manifestations or integumentary signs, but not both.

Probable VKH disease

Patients with probable VKH disease include those with isolated ocular disease.

Next

Etiology

VKH disease currently is considered to be a cell-mediated autoimmune disease directed against melanocytes. However, the pathogenesis of VKH disease is uncertain, although the wide spectrum of findings in this disorder suggests a central mechanism to account for the multisystemic manifestations. Inflammation and loss of melanocytes have been described in a number of tissues, including the skin, inner ear, meninges, and uvea. These histopathologic changes suggest an infectious or autoimmune basis for the disease.

The possibility that VKH disease has an autoimmune pathogenesis is supported by the statistically significant frequency of HLA-DR4, an antigen commonly associated with other autoimmune diseases.

An autoimmune reaction seems to be directed against an antigenic component shared by uveal, dermal, and meningeal melanocytes. The exact target antigen has not been identified, but possible candidates include tyrosinase- or tyrosinase-related proteins,[13, 14, 15] an unidentified 75-kd protein obtained from cultured human melanoma cells (G-361),[13] and S-100 protein.[16] Evidence suggests that Th1 and Th17 subsets of T cells together with the cytokines interleukin (IL)-7, IL-17 and IL-23 are likely involved in the initiation and maintenance of the inflammatory process.[17, 18, 19]

VKH disease can be associated with other autoimmune disorders, such as autoimmune polyglandular syndrome,[20] hypothyroidism, Hashimoto thyroiditis, diabetes mellitus,[21, 22] Guillain-Barré syndrome,[23] and immunoglobulin A (IgA) nephropathy.[24] This syndrome has also been reported to be linked to malignant lymphoma.[25]

Immunologic analysis of cerebrospinal fluid (CSF) lymphocytes in VKH disease and studies of human uveal melanocytes show that uveal pigment can stimulate lymphocyte cultures from patients with VKH syndrome. Lymphocytes of peripheral blood and CSF from these patients may reveal in vitro cytotoxicity against allogenic melanoma cells.

Circulating antibodies against a retinal photoreceptor region have been detected in patients with this disorder.

The clinical course of VKH disease with an influenzalike episode suggests a viral or postinfectious origin. Some studies invoke a possible role of Epstein-Barr virus reactivation in this disease.[26] Although a viral cause has been proposed, however, no virus has been isolated or cultured from patients with VKH disease. Nonetheless, Schlaegel and Morris found viruslike inclusion bodies in the subretinal fluid of a patient with the disorder.[27]

Single reports of patients developing VKH disease after cutaneous injury have been noted,[28, 29] as well as 2 cases of this condition occurring after bacillus Calmette Guérin (BCG) therapy for melanoma[30] and 1 case following surgery for metastatic malignant melanoma.[31] Case reports indicate that even an indirect trauma in melanocyte-containing tissue may induce an inflammatory response in the eye, with VKH disease following a closed head trauma.[32]

A study revealed that a decreased vitamin D-3 level has been associated with active intraocular inflammation in patients with VKH disease.[33]

Genetics

Although almost all instances of VKH syndrome are sporadic, and familial cases are rare, some authors suggest that the condition may be inherited, probably as an autosomal recessive trait.

The strong association between VKH disease and certain racial and ethnic groups suggests that the disorder may have an immunogenetic predisposition.[34] HLA typing can be useful to identify these common genetic factors, with several HLA haplotypes apparently being more common in certain populations with VKH disease.

Among Japanese patients, HLA-DR4, HLA-DR53, and HLA-DQ4 are associated strongly with the disease.[35] In Chinese patients, HLA associations are seen with HLA-DR4, HLA-DR53, and HLA-DQ7.[36] In a mixed group of American patients, Davis and colleagues found an association with HLA-DR4 and HLA-DR53, while HLA-DR1 and HLA-DR4 were reported in Hispanic patients living in southern California.[37]

An association with HLA-DR4, HLA-DRw53, and HLA-DQw3 has been found in subjects of Native American ancestry, and HLA-DR4 also was found to be significantly related to VKH syndrome in white Europeans, specifically in Italian patients.[38]

Data indicate that patients with VKH disease are sensitized to melanocyte epitopes and display a peptide-specific Th1 cytokine response. Patients bearing HLA-DRB1*0405 recognize a broader melanocyte-derived peptide repertoire, so the presence of this allele increases susceptibility to the development of VKH disease.[39] In a group of French VKH disease DRB1*04-positive patients, the HLA-DRB1*0405 subtype was found in 71% of them.[40]

Previous
Next

Epidemiology

VKH disease is uncommon, but it may be seen in Asian (primarily from eastern and southeastern Asia), Middle Eastern, Hispanic, and Native American populations. The disorder is extremely uncommon in whites.[41, 42]

In Japan, VKH disease represents 7-8% of all patients with uveitis.[43] This disorder rarely is seen in Northern European individuals. (The manifestations of VKH disease in whites resemble those in the Japanese population, but cutaneous signs are much rarer.)

Race-related demographics

In a report from the National Eye Institute, Nussenblatt et al noted that among patients with VKH disease in the study, 50% were white, 35% were African American, and 13% were Hispanic; however, most patients had remote Native American ancestry.[44]

VKH disease is one of the most common forms of uveitis among darkly pigmented races. Individuals with the disorder most likely have an immunogenetic predisposition that is probably more common in certain ethnic groups with increased skin pigmentation, such as Asian, Middle Eastern, Hispanic, and Native American populations. Moreover, VKH disease is distinctly uncommon in Africans, reaffirming that skin pigmentation alone is not a predisposing factor in the pathogenesis of the disease.

Sex- and age-related demographics

Females are more commonly affected than males; the female-to-male ratio in most large series is 2:1.

The age of onset of VKH disease has been reported to range from 3-89 years, with the maximum frequency in persons in their 30s. VKH disease in children often goes unrecognized.[45]

Previous
Next

Prognosis

Long-term complications of VKH disease include reversible and irreversible vision loss. In patients with this disorder, vision loss is often is due to cataracts, glaucoma, and choroidal neovascularization (with this last being a major cause of late vision loss). Patients with optic disc swelling may develop visual field defects that persist following resolution of the inflammation.[46] Final visual outcome depends on the rapidity and appropriateness of treatment.[47]

The prognosis may be improved by the use of early, high-dose corticosteroids during the acute phase of the disease and afterward a slow tapering reduction in dosage until therapy is discontinued. In most cases, therapy should not be discontinued during the 3 months after onset of the disease, because of the high rate of recurrence during this period. Many patients require a tapering period of at least 3-6 months before the corticosteroids can be discontinued.

Ocular complications of VKH disease are more severe in children than in adults, leading to rapid deterioration in vision.

Complications

VKH disease is not associated with mortality. Complications of the disorder include the following:

  • Cataract
  • Closed-angle glaucoma - Pupillary block, forward rotation of the ciliary body
  • Subretinal fibrosis
  • Choroidal neovascularization
  • Neovascularization of the disc
  • Pigmentary changes of the fundus
  • Optic atrophy
  • Neurologic manifestations - Many of the neurologic manifestations may persist for weeks; most signs and symptoms resolve with corticosteroid therapy, although severe meningoencephalitic impairment has been reported
  • Cutaneous manifestations - Most of the integumentary changes, including alopecia, poliosis, and vitiligo, persist despite therapy; cutaneous changes may be permanent
  • Auditory manifestations - Inner ear manifestations typically respond to corticosteroid therapy within weeks to months; hearing is restored completely in most patients with VKH disease
Previous
 
 
Contributor Information and Disclosures
Author

R Christopher Walton, MD Professor, Director of Uveitis and Ocular Inflammatory Disease Service, Department of Ophthalmology, University of Tennessee College of Medicine

R Christopher Walton, MD is a member of the following medical societies: American Academy of Ophthalmology, Association for Research in Vision and Ophthalmology, Retina Society, American College of Healthcare Executives, American Uveitis Society

Disclosure: Nothing to disclose.

Coauthor(s)

Camila K Janniger, MD Clinical Professor of Dermatology, Clinical Associate Professor of Pediatrics, Chief of Pediatric Dermatology, Rutgers New Jersey Medical School

Camila K Janniger, MD is a member of the following medical societies: American Academy of Dermatology

Disclosure: Nothing to disclose.

Anna Choczaj-Kukula, MD, PhD Locum Consultant Dermatologist, Barnet and Chase Farm NHS Trust; Honorary Clinical Research Fellow, Royal Free Hospital, UK

Anna Choczaj-Kukula, MD, PhD is a member of the following medical societies: American Academy of Dermatology, Royal Society of Medicine, European Academy of Dermatology and Venereology, British Association of Dermatologists

Disclosure: Partner received salary from Johnson & Johnson for management position.

Chief Editor

Hampton Roy, Sr, MD Associate Clinical Professor, Department of Ophthalmology, University of Arkansas for Medical Sciences

Hampton Roy, Sr, MD is a member of the following medical societies: American Academy of Ophthalmology, American College of Surgeons, Pan-American Association of Ophthalmology

Disclosure: Nothing to disclose.

Acknowledgements

David F Butler, MD Professor of Dermatology, Texas A&M University College of Medicine; Chair, Department of Dermatology, Director, Dermatology Residency Training Program, Scott and White Clinic, Northside Clinic

David F Butler, MD is a member of the following medical societies: Alpha Omega Alpha, American Academy of Dermatology, American Medical Association, American Society for Dermatologic Surgery, American Society for MOHS Surgery, Association of Military Dermatologists, and Phi Beta Kappa

Disclosure: Nothing to disclose.

Steve Charles, MD Director of Charles Retina Institute; Clinical Professor, Department of Ophthalmology, University of Tennessee College of Medicine; Adjunct Professor of Ophthalmology, Columbia College of Physicians and Surgeons; Clinical Professor Ophthalmology, Chinese University of Hong Kong

Steve Charles, MD is a member of the following medical societies: American Academy of Ophthalmology, American Society of Retina Specialists, Club Jules Gonin, Macula Society, and Retina Society

Disclosure: Alcon Laboratories Consulting fee Consulting; OptiMedica Ownership interest Other; Topcon Medical Lasers Consulting fee Consulting

Anna Choczaj-Kukula, MD, PhD Locum Consultant Dermatologist, St John's Institute of Dermatology, St Thomas' Hospital, UK

Anna Choczaj-Kukula, MD, PhD is a member of the following medical societies: American Academy of Dermatology, British Association of Dermatologists, European Academy of Dermatology and Venereology, and Royal Society of Medicine

Disclosure: Johnson & Johnson Salary Management position

Dirk M Elston, MD Director, Ackerman Academy of Dermatopathology, New York

Dirk M Elston, MD is a member of the following medical societies: American Academy of Dermatology

Disclosure: Nothing to disclose.

Janet Fairley, MD Professor and Head, Department of Dermatology, University of Iowa, Roy J and Lucille A Carver College of Medicine

Janet Fairley, MD is a member of the following medical societies: American Academy of Dermatology, American Dermatological Association, American Federation for Medical Research, and Society for Investigative Dermatology

Disclosure: Nothing to disclose.

Camila K Janniger, MD Clinical Professor of Dermatology, Clinical Associate Professor of Pediatrics, Chief of Pediatric Dermatology, University of Medicine and Dentistry of New Jersey-New Jersey Medical School

Camila K Janniger, MD is a member of the following medical societies: American Academy of Dermatology

Disclosure: Nothing to disclose.

Robert A Schwartz, MD, MPH Professor and Head, Dermatology, Professor of Pathology, Pediatrics, Medicine, and Preventive Medicine and Community Health, University of Medicine and Dentistry of New Jersey-New Jersey Medical School

Robert A Schwartz, MD, MPH is a member of the following medical societies: Alpha Omega Alpha, American Academy of Dermatology, American College of Physicians, and Sigma Xi

Disclosure: Nothing to disclose.

John D Sheppard Jr, MD, MMSc Professor of Ophthalmology, Microbiology and Molecular Biology, Clinical Director, Thomas R Lee Center for Ocular Pharmacology, Ophthalmology Residency Research Program Director, Eastern Virginia Medical School; President, Virginia Eye Consultants

John D Sheppard Jr, MD, MMSc is a member of the following medical societies: American Academy of Ophthalmology, American Society for Microbiology, American Society of Cataract and Refractive Surgery, American Uveitis Society, and Association for Research in Vision and Ophthalmology

Disclosure: Nothing to disclose.

Francisco Talavera, PharmD, PhD Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Medscape Salary Employment

References
  1. Andreoli CM, Foster CS. Vogt-Koyanagi-Harada disease. Int Ophthalmol Clin. 2006 Spring. 46(2):111-22. [Medline].

  2. Rajendram R, Evans M, Rao NA. Vogt-Koyanagi-Harada disease. Int Ophthalmol Clin. 2005 Spring. 45(2):115-34. [Medline].

  3. Yang P, Ren Y, Li B, Fang W, Meng Q, Kijlstra A. Clinical characteristics of Vogt-Koyanagi-Harada syndrome in Chinese patients. Ophthalmology. 2007 Mar. 114(3):606-14. [Medline].

  4. Usui Y, Goto H, Sakai J, Takeuchi M, Usui M, Rao NA. Presumed Vogt-Koyanagi-Harada disease with unilateral ocular involvement: report of three cases. Graefes Arch Clin Exp Ophthalmol. 2009 Aug. 247(8):1127-32. [Medline].

  5. da Silva FT, Damico FM, Marin ML, Goldberg AC, Hirata CE, Takiuti PH, et al. Revised diagnostic criteria for vogt-koyanagi-harada disease: considerations on the different disease categories. Am J Ophthalmol. 2009 Feb. 147(2):339-345.e5. [Medline].

  6. PATTISON EM. UVEOMENINGOENCEPHALITIC SYNDROME (VOGT-KOYANAGI-HARADA). Arch Neurol. 1965 Feb. 12:197-205. [Medline].

  7. Vogt A. Frühzeitiges Ergrauen der Zilien und Bemerkungen uber den sogenannten plötzlichen Eintritt dieser Veranderung. Klin Monatsbl Augenheilk. 1906;44:228-42.

  8. Harada E. On the acute diffuse choroiditis. Acta Soc Ophthalmol Jpn. 1926;30:356-78.

  9. Koyanagi Y. Dysakusis, Alopecia und Poliosis bei schwerer Uveitis nicht traumatischen Ursprungs. Klin Monatsbl Augenheilk. 1929;82:194-211.

  10. Babel J. Syndrome de Vogt-Koyanagi. Schweiz Med Wochenscher. 1932;44:1136.

  11. Read RW, Holland GN, Rao NA, Tabbara KF, Ohno S, Arellanes-Garcia L, et al. Revised diagnostic criteria for Vogt-Koyanagi-Harada disease: report of an international committee on nomenclature. Am J Ophthalmol. 2001 May. 131(5):647-52. [Medline].

  12. Nordlund JJ, Albert D, Forget B, Lerner AB. Halo nevi and the Vogt-Koyanagi-Harada syndrome. Manifestations of vitiligo. Arch Dermatol. 1980 Jun. 116(6):690-2. [Medline].

  13. Kondo I, Yamagata K, Yamaki K, Sakuragi S. [Analysis of the candidate antigen for Harada's disease]. Nihon Ganka Gakkai Zasshi. 1994 Jun. 98(6):596-603. [Medline].

  14. Yamaki K, Gocho K, Hayakawa K, Kondo I, Sakuragi S. Tyrosinase family proteins are antigens specific to Vogt-Koyanagi-Harada disease. J Immunol. 2000 Dec 15. 165(12):7323-9. [Medline].

  15. Hashimoto T, Takizawa H, Yukimura K, Ohta K. Vogt-Koyanagi-Harada disease associated with brainstem encephalitis. J Clin Neurosci. 2009 Apr. 16(4):593-5. [Medline].

  16. Gloddek B, Lassmann S, Gloddek J, Arnold W. Role of S-100beta as potential autoantigen in an autoimmune disease of the inner ear. J Neuroimmunol. 1999 Nov 1. 101(1):39-46. [Medline].

  17. El-Asrar AM, Struyf S, Kangave D, Al-Obeidan SS, Opdenakker G, Geboes K, et al. Cytokine profiles in aqueous humor of patients with different clinical entities of endogenous uveitis. Clin Immunol. 2011 May. 139(2):177-84. [Medline].

  18. Chi W, Yang P, Li B, Wu C, Jin H, Zhu X, et al. IL-23 promotes CD4+ T cells to produce IL-17 in Vogt-Koyanagi-Harada disease. J Allergy Clin Immunol. 2007 May. 119(5):1218-24. [Medline].

  19. Yang Y, Xiao X, Li F, Du L, Kijlstra A, Yang P. Increased IL-7 expression in Vogt-Koyanagi-Harada disease. Invest Ophthalmol Vis Sci. 2012 Feb. 53(2):1012-7. [Medline].

  20. Kluger N, Mura F, Guillot B, Bessis D. Vogt-koyanagi-harada syndrome associated with psoriasis and autoimmune thyroid disease. Acta Derm Venereol. 2008. 88(4):397-8. [Medline].

  21. Al Hemidan AI, Tabbara KF, Althomali T. Vogt-Koyanagi-Harada associated with diabetes mellitus and celiac disease in a 3-year-old girl. Eur J Ophthalmol. 2006 Jan-Feb. 16(1):173-7. [Medline].

  22. Suzuki H, Isaka M, Suzuki S. Type 1 diabetes mellitus associated with Graves' disease and Vogt-Koyanagi-Harada syndrome. Intern Med. 2008. 47(13):1241-4. [Medline].

  23. Najman-Vainer J, Levinson RD, Graves MC, Nguyen BT, Engstrom RE Jr, Holland GN. An association between Vogt-Koyanagi-Harada disease and Guillain-Barré syndrome. Am J Ophthalmol. 2001 May. 131(5):615-9. [Medline].

  24. Matsuo T, Masuda I, Ota K, Yamadori I, Sunami R, Nose S. Vogt-Koyanagi-Harada syndrome in two patients with immunoglobulin A nephropathy. Acta Med Okayama. 2007 Oct. 61(5):305-9. [Medline].

  25. Hashida N, Kanayama S, Kawasaki A, Ogawa K. A case of vogt-koyanagi-harada disease associated with malignant lymphoma. Jpn J Ophthalmol. 2005 May-Jun. 49(3):253-6. [Medline].

  26. Sunakawa M, Okinami S. Epstein-Barr virus-related antibody pattern in uveitis. Jpn J Ophthalmol. 1985. 29(4):423-8. [Medline].

  27. SCHLAEGEL TF Jr, MORRIS WR. VIRUSLIKE INCLUSION BODIES IN SUBRETINAL FLUID IN UVEO-ENCEPHALITIS. Am J Ophthalmol. 1964 Dec. 58:940-5. [Medline].

  28. Tabbara KF. Vogt-Koyanagi-Harada syndrome after cutaneous injury. Ophthalmology. 1999 Oct. 106(10):1854-5. [Medline].

  29. Rathinam SR, Namperumalsamy P, Nozik RA, Cunningham ET Jr. Vogt-Koyanagi-Harada syndrome after cutaneous injury. Ophthalmology. 1999 Mar. 106(3):635-8. [Medline].

  30. Donaldson RC, Canaan SA Jr, McLean RB, Ackerman LV. Uveitis and vitiligo associated with BCG treatment for malignant melanoma. Surgery. 1974 Nov. 76(5):771-8. [Medline].

  31. Sober AJ, Haynes HA. Uveitis, poliosis, hypomelanosis, and alopecia in a patient with malignant melanoma. Arch Dermatol. 1978 Mar. 114(3):439-41. [Medline].

  32. Accorinti M, Pirraglia MP, Corsi C, Caggiano C. Vogt-Koyanagi-Harada disease after head trauma. Eur J Ophthalmol. 2007 Sep-Oct. 17(5):847-52. [Medline].

  33. Yi X, Yang P, Sun M, Yang Y, Li F. Decreased 1,25-Dihydroxyvitamin D3 level is involved in the pathogenesis of Vogt-Koyanagi-Harada (VKH) disease. Mol Vis. 2011 Mar 9. 17:673-9. [Medline]. [Full Text].

  34. Levinson RD, Du Z, Luo L, Holland GN, Rao NA, Reed EF, et al. KIR and HLA gene combinations in Vogt-Koyanagi-Harada disease. Hum Immunol. 2008 Jun. 69(6):349-53. [Medline].

  35. Horie Y, Takemoto Y, Miyazaki A, Namba K, Kase S, Yoshida K, et al. Tyrosinase gene family and Vogt-Koyanagi-Harada disease in Japanese patients. Mol Vis. 2006 Dec 20. 12:1601-5. [Medline].

  36. Hou S, Yang P, Du L, Zhou H, Lin X, Liu X, et al. Small ubiquitin-like modifier 4 (SUMO4) polymorphisms and Vogt-Koyanagi-Harada (VKH) syndrome in the Chinese Han population. Mol Vis. 2008. 14:2597-603. [Medline]. [Full Text].

  37. Davis JL, Mittal KK, Freidlin V, Mellow SR, Optican DC, Palestine AG, et al. HLA associations and ancestry in Vogt-Koyanagi-Harada disease and sympathetic ophthalmia. Ophthalmology. 1990 Sep. 97(9):1137-42. [Medline].

  38. Pivetti-Pezzi P, Accorinti M, Colabelli-Gisoldi RA, Pirraglia MP. Vogt-Koyanagi-Harada disease and HLA type in Italian patients. Am J Ophthalmol. 1996 Dec. 122(6):889-91. [Medline].

  39. Goldberg AC, Yamamoto JH, Chiarella JM, Marin ML, Sibinelli M, Neufeld R, et al. HLA-DRB1*0405 is the predominant allele in Brazilian patients with Vogt-Koyanagi-Harada disease. Hum Immunol. 1998 Mar. 59(3):183-8. [Medline].

  40. Abad S, Monnet D, Caillat-Zucman S, Mrejen S, Blanche P, Chalumeau M, et al. Characteristics of Vogt-Koyanagi-Harada disease in a French cohort: ethnicity, systemic manifestations, and HLA genotype data. Ocul Immunol Inflamm. 2008 Jan-Feb. 16(1):3-8. [Medline].

  41. Chee SP, Jap A, Bacsal K. Prognostic factors of Vogt-Koyanagi-Harada disease in Singapore. Am J Ophthalmol. 2009 Jan. 147(1):154-161.e1. [Medline].

  42. Ostergaard J, Goldschmidt E, Andersen N. Vogt-Koyanagi-Harada syndrome in a Greenlandic Inuit. Acta Ophthalmol. 2008 Aug. 86(5):576-8. [Medline].

  43. Ohguro N, Sonoda KH, Takeuchi M, Matsumura M, Mochizuki M. The 2009 prospective multi-center epidemiologic survey of uveitis in Japan. Jpn J Ophthalmol. 2012 Sep. 56(5):432-5. [Medline].

  44. Nussenblatt RB. Clinical studies of Vogt-Koyanagi-Harada's disease at the National Eye Institute, NIH, USA. Jpn J Ophthalmol. 1988. 32(3):330-3. [Medline].

  45. Berker N, Ozdamar Y, Soykan E, Ozdal P, Ozkan SS. Vogt-Koyanagi-Harada syndrome in children: report of a case and review of the literature. Ocul Immunol Inflamm. 2007 Jul-Aug. 15(4):351-7. [Medline].

  46. Nakao K, Abematsu N, Mizushima Y, Sakamoto T. Optic disc swelling in Vogt-Koyanagi-Harada disease. Invest Ophthalmol Vis Sci. 2012 Apr. 53(4):1917-22. [Medline].

  47. Read RW, Yu F, Accorinti M, Bodaghi B, Chee SP, Fardeau C, et al. Evaluation of the effect on outcomes of the route of administration of corticosteroids in acute Vogt-Koyanagi-Harada disease. Am J Ophthalmol. 2006 Jul. 142(1):119-24. [Medline].

  48. Bacsal K, Wen DS, Chee SP. Concomitant choroidal inflammation during anterior segment recurrence in Vogt-Koyanagi-Harada disease. Am J Ophthalmol. 2008 Mar. 145(3):480-486. [Medline].

  49. Errera MH, Fardeau C, Cohen D, Navarro A, Gaudric A, Bodaghi B, et al. Effect of the duration of immunomodulatory therapy on the clinical features of recurrent episodes in Vogt--Koyanagi--Harada disease. Acta Ophthalmol. 2011 Jun. 89(4):e357-66. [Medline].

  50. Nakao K, Abematsu N, Mizushima Y, Sakamoto T. Optic disc swelling in Vogt-Koyanagi-Harada disease. Invest Ophthalmol Vis Sci. 2012 Apr. 53(4):1917-22. [Medline].

  51. Pahk PJ, Todd DJ, Blaha GR, Soukiasian SH, Landmann DS, Craven DE, et al. Intravascular lymphoma masquerading as Vogt-Koyanagi-Harada syndrome. Ocul Immunol Inflamm. 2008 May-Jun. 16(3):123-6. [Medline].

  52. Kitaichi N, Matoba H, Ohno S. The positive role of lumbar puncture in the diagnosis of Vogt-Koyanagi-Harada disease: lymphocyte subsets in the aqueous humor and cerebrospinal fluid. Int Ophthalmol. 2007 Apr-Jun. 27(2-3):97-103. [Medline].

  53. Ondrey FG, Moldestad E, Mastroianni MA, Pikus A, Sklare D, Vernon E, et al. Sensorineural hearing loss in Vogt-Koyanagi-Harada syndrome. Laryngoscope. 2006 Oct. 116(10):1873-6. [Medline].

  54. Arellanes-García L, Hernández-Barrios M, Fromow-Guerra J, Cervantes-Fanning P. Fluorescein fundus angiographic findings in Vogt-Koyanagi-Harada syndrome. Int Ophthalmol. 2007 Apr-Jun. 27(2-3):155-61. [Medline].

  55. Wu W, Wen F, Huang S, Luo G, Wu D. Indocyanine green angiographic findings of Dalen-Fuchs nodules in Vogt-Koyanagi-Harada disease. Graefes Arch Clin Exp Ophthalmol. 2007 Jul. 245(7):937-40. [Medline].

  56. Chee SP, Jap A, Cheung CM. The prognostic value of angiography in Vogt-Koyanagi-Harada disease. Am J Ophthalmol. 2010 Dec. 150(6):888-93. [Medline].

  57. Bouchenaki N, Herbort CP. Indocyanine green angiography guided management of vogt-koyanagi-harada disease. J Ophthalmic Vis Res. 2011 Oct. 6(4):241-8. [Medline]. [Full Text].

  58. da Silva FT, Hirata CE, Sakata VM, Olivalves E, Preti R, Pimentel S, et al. Indocyanine green angiography findings in patients with long-standing Vogt-koyanagi-Harada disease: a cross-sectional study. BMC Ophthalmol. 2012 Aug 13. 12(1):40. [Medline].

  59. Maruko I, Iida T, Sugano Y, Oyamada H, Sekiryu T, Fujiwara T, et al. Subfoveal choroidal thickness after treatment of Vogt-Koyanagi-Harada disease. Retina. 2011 Mar. 31(3):510-7. [Medline].

  60. Lohman BD, Gustafson CA, McKinney AM, Sarikaya B, Silbert SC. MR imaging of Vogt-Koyanagi-Harada syndrome with leptomeningeal enhancement. AJNR Am J Neuroradiol. 2011 Oct. 32(9):E169-71. [Medline].

  61. Han HJ, Kim HY, Park JH, Lee EJ, Kim do G, Shin DI. Magnetic resonance imaging of pachymeningeal enhancement in Vogt-Koyanagi-Harada disease. Neurol Sci. 2010 Dec. 31(6):785-8. [Medline].

  62. Kim SJ, Yu HG. The use of low-dose azathioprine in patients with Vogt-Koyanagi-Harada disease. Ocul Immunol Inflamm. 2007 Sep-Oct. 15(5):381-7. [Medline].

  63. Agarwal M, Ganesh SK, Biswas J. Triple agent immunosuppressive therapy in Vogt-Koyanagi-Harada syndrome. Ocul Immunol Inflamm. 2006 Dec. 14(6):333-9. [Medline].

  64. Choudhary A, Harding SP, Bucknall RC, Pearce IA. Mycophenolate mofetil as an immunosuppressive agent in refractory inflammatory eye disease. J Ocul Pharmacol Ther. 2006 Jun. 22(3):168-75. [Medline].

  65. Nussenblatt RB, Palestine AG, Chan CC. Cyclosporin A therapy in the treatment of intraocular inflammatory disease resistant to systemic corticosteroids and cytotoxic agents. Am J Ophthalmol. 1983 Sep. 96(3):275-82. [Medline].

  66. Yamaguchi Y, Otani T, Kishi S. Tomographic features of serous retinal detachment with multilobular dye pooling in acute Vogt-Koyanagi-Harada disease. Am J Ophthalmol. 2007 Aug. 144(2):260-5. [Medline].

  67. Tellier Z. Human immunoglobulins in intraocular inflammation. Ann N Y Acad Sci. 2007 Sep. 1110:337-47. [Medline].

  68. González-Delgado M, González C, Blázquez JI, Salas-Puig J, Castro J, Hernández-Lahoz C. [Intravenous immunoglobulin therapy in Vogt-Koyanagi-Harada syndrome]. Neurologia. 2004 Sep. 19(7):401-3. [Medline].

  69. Wang Y, Gaudio PA. Infliximab therapy for 2 patients with Vogt-Koyanagi-Harada syndrome. Ocul Immunol Inflamm. 2008 Jul-Aug. 16(4):167-71. [Medline].

  70. Kahn P, Weiss M, Imundo LF, Levy DM. Favorable response to high-dose infliximab for refractory childhood uveitis. Ophthalmology. 2006 May. 113(5):860-4.e2. [Medline].

  71. Moreker MR, Lodhi SA, Pathengay A. Role of intravitreal triamcinolone as an adjuvant in the management of Vogt-Koyanagi-Harada disease. Indian J Ophthalmol. 2007 Nov-Dec. 55(6):479-80. [Medline]. [Full Text].

  72. Perente I, Utine CA, Cakir H, Kaya V, Tutkun IT, Yilmaz OF. Management of ocular complications of Vogt-Koyanagi-Harada syndrome. Int Ophthalmol. 2009 Feb. 29(1):33-7. [Medline].

 
Previous
Next
 
Bilateral, multifocal serous detachments in a patient with Vogt-Koyanagi-Harada disease. Disc hyperemia is evident in the right eye.
Fluorescein angiography of the left eye in a patient with Vogt-Koyanagi-Harada disease. Midphase is shown on the left, with multiple areas of hyperfluorescence at the level of the retinal pigment epithelium (RPE). Late phase on the same angiogram (right) reveals multiple placoid areas of hyperfluorescence at the level of the RPE and pooling of dye in the areas of serous detachment.
Patient with progressive dysacusis and recent onset of visual loss. Fundus photo shows a large, multifocal serous detachment of the right eye. B-scan ultrasonography reveals posterior choroidal thickening with an overlying retinal detachment.
Patient with progressive dysacusis and recent onset of visual loss is shown here following 6 weeks of systemic corticosteroid therapy. Diffuse depigmentation of the choroid with retinal pigment epithelium migration is seen. Residual retinal striae are present in the peripapillary region. B-scan ultrasonography shows resolution of retinal detachment and choroidal thickening.
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2016 by WebMD LLC. This website also contains material copyrighted by 3rd parties.